Proteomic profiling identifies co-regulated expression of splicing factors as a characteristic feature of intravenous leiomyomatosis

Show simplified metadata
dc.contributor.affiliationThe Institute of Cancer Research; The Royal Marsden NHS Foundation Trust; University Hospitals Birmingham NHS Foundation Trusten_US
dc.contributor.authorKrasny, Lukas
dc.contributor.authorWilding, Chris P
dc.contributor.authorPerkins, Emma
dc.contributor.authorArthur, Amani
dc.contributor.authorGuljar, Nafia
dc.contributor.authorJenks, Andrew D
dc.contributor.authorFisher, Cyril
dc.contributor.authorJudson, Ian
dc.contributor.authorThway, Khin
dc.contributor.authorJones, Robin L
dc.contributor.authorHuang, Paul H
dc.contributor.departmentCellular Pathologyen_US
dc.contributor.roleMedical and Dentalen_US
dc.contributor.trustauthorFisher, Cyril
dc.date.accessioned2024-10-31T12:00:58Z
dc.date.available2024-10-31T12:00:58Z
dc.date.issued2022-06-13
dc.description.abstractIntravenous leiomyomatosis (IVLM) is a rare benign smooth muscle tumour that is characterised by intravenous growth in the uterine and pelvic veins. Previous DNA copy number and transcriptomic studies have shown that IVLM harbors unique genomic and transcriptomic alterations when compared to uterine leiomyoma (uLM), which may account for their distinct clinical behaviour. Here we undertake the first comparative proteomic analysis of IVLM and other smooth muscle tumours (comprising uLM, soft tissue leiomyoma and benign metastasizing leiomyoma) utilising data-independent acquisition mass spectrometry. We show that, at the protein level, IVLM is defined by the unique co-regulated expression of splicing factors. In particular, IVLM is enriched in two clusters composed of co-regulated proteins from the hnRNP, LSm, SR and Sm classes of the spliceosome complex. One of these clusters (Cluster 3) is associated with key biological processes including nascent protein translocation and cell signalling by small GTPases. Taken together, our study provides evidence of co-regulated expression of splicing factors in IVLM compared to other smooth muscle tumours, which suggests a possible role for alternative splicing in the pathogenesis of IVLM.en_US
dc.identifier.citationKrasny L, Wilding CP, Perkins E, Arthur A, Guljar N, Jenks AD, Fisher C, Judson I, Thway K, Jones RL, Huang PH. Proteomic Profiling Identifies Co-Regulated Expression of Splicing Factors as a Characteristic Feature of Intravenous Leiomyomatosis. Cancers (Basel). 2022 Jun 13;14(12):2907. doi: 10.3390/cancers14122907.en_US
dc.identifier.doi10.3390/cancers14122907
dc.identifier.eissn2072-6694
dc.identifier.pmid35740573
dc.identifier.urihttp://hdl.handle.net/20.500.14200/6303
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.relation.urlhttps://www.mdpi.com/journal/cancersen_US
dc.source.countrySwitzerland
dc.source.issue12
dc.source.journaltitleCancersen_US
dc.source.volume14
dc.subjectOncology. Pathology.en_US
dc.titleProteomic profiling identifies co-regulated expression of splicing factors as a characteristic feature of intravenous leiomyomatosisen_US
dc.typeArticleen_US
dspace.entity.typePublication
oa.grant.openaccessnaen_US
rioxxterms.versionNAen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.7 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
UHB Oncology